SBBP Strongbridge Biopharma PLC

Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that the Company will hold its Annual General Meeting (AGM) of Shareholders on Tuesday, May 15, 2018 at the offices of Arthur Cox, Ten Earlsfort Terrace, Dublin, Ireland. The record date for shareholders entitled to receive notice of and vote at the AGM is Wednesday, March 28, 2018.

About Strongbridge Biopharma Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's commercial portfolio within its rare neuromuscular and rare endocrine franchises includes Keveyis®(dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis, and Macrilen™ (macimorelin), the first and only FDA-approved oral drug indicated for the diagnosis of adult growth hormone deficiency. The Company’s rare endocrine franchise also includes a clinical-stage pipeline of therapies: Recorlev™ (levoketoconazole), a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome, and veldoreotide, a next-generation somatostatin analog being investigated for the treatment of acromegaly, with potential additional applications in other conditions amenable to somatostatin receptor activation.

Contacts:

Corporate and Media Relations Elixir Health Public Relations Lindsay Rocco +1 862-596-1304 lrocco@elixirhealthpr.com

Investor RelationsUnited States:The Trout Group Marcy Nanus +1 646-378-2927 mnanus@troutgroup.com

Europe:First HouseMitra Hagen Negård+47 21 04 62 19strongbridgebio@firsthouse.no

USA 900 Northbrook Drive Suite 200 Trevose, PA 19053 Tel. +1 610-254-9200 Fax. +1 215-355-7389